IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types

Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma

Black patients show inferior survival despite similar cytogenetics and treatment response

Asciminib shows high molecular response, favourable safety in 2L CML-CP

Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients

First-line use of tepotinib in METex14 NSCLC: A patient-centered journey

Non-covalent BTK inhibitor pirtobrutinib shows promise as frontline therapy for CLL/SLL

Linvoseltamab monotherapy in newly diagnosed multiple myeloma shows impressive frontline responses

Pimicotinib in TGCT demonstrates durable responses and sustained functional improvement